下一代糖尿病藥物傳輸市場規模、佔有率和成長分析（按產品、人口統計、適應症、最終用戶和地區分類）—產業預測，2025-2032年

全球下一代糖尿病藥物輸送市場預計在 2023 年達到 363 億美元，從 2024 年的 393.1 億美元成長到 2032 年的 744 億美元，在預測期（2025-2032 年）內複合年成長率為 8.3%。

全球新一代糖尿病藥物傳輸市場正經歷顯著成長，這主要得益於全球糖尿病盛行率的不斷攀升。這推動了對更有效、更便利、更微創治療方法的需求。研究重點正從單純控制血糖值轉向開發能夠促進減重、改善心血管健康並最終提升患者生活品質的治療方法，從而促進研發投入和市場擴張。然而，分析顯示，該市場仍面臨許多挑戰，包括創新治療方法和醫療設備的高成本，阻礙了健保報銷和病患可近性。此外，冗長且成本高昂的監管核准流程，以及開發可靠的非侵入式系統和全自動「閉合迴路」管理系統的技術壁壘，也對未來的市場成長構成重大阻礙。

全球下一代糖尿病藥物傳輸市場促進因素

全球新一代糖尿病藥物傳輸市場的顯著擴張主要受1型和2型糖尿病盛行率持續上升的驅動。越來越多的患者需要有效的治療措施，凸顯了市場對創新便利治療方案的巨大需求。隨著確診病例的增多，開發能夠滿足多樣化醫療需求的先進藥物輸送系統變得至關重要，這進一步推動了市場成長。治療方法方案的拓展不僅旨在改善患者預後，更致力於簡化糖尿病管理，以掌握不斷擴大的市場機會。

限制全球下一代糖尿病藥物輸送市場發展的因素

全球新一代糖尿病藥物傳輸市場面臨的主要挑戰之一是這些先進治療方法和設備的高昂成本，這往往超出了許多患者的經濟承受能力。這種經濟負擔使得患者難以獲得必要的治療。此外，從公共和私人保險公司獲得報銷也存在許多障礙，這進一步限制了患者獲得這些重要治療方法的機會，尤其是在醫療資源有限的新興市場。消除這些經濟障礙對於確保創新糖尿病療法的更廣泛應用至關重要。

糖尿病治療用下一代藥物輸送系統的全球市場趨勢

全球下一代糖尿病藥物輸送市場的發展動力源於對設備間互通性和互聯性日益成長的需求。患者正在尋求能夠將持續血糖監測儀 (CGM) 與胰島素幫浦整合的個人化解決方案，這催生了開放通訊協定系統的趨勢。這項轉變不僅增強了患者的自主性，還透過實現無縫資料交換最佳化了糖尿病管理。隨著製造商積極響應這一主導需求，我們預計將湧現出更多創新藥物傳輸解決方案，這些方案將優先考慮方便用戶使用的應用程式、更便捷的數據存取以及更佳的治療效果。這將為糖尿病護理領域創造一個更互聯互通的環境。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球下一代糖尿病藥物傳輸市場規模（按產品和複合年成長率分類）（2025-2032 年）

• 市場概覽
• 吸入式胰島素
• 口服胰島素
• 胰島素貼劑
• CGM系統
• 人工胰臟

全球下一代糖尿病藥物輸送市場按人口統計和複合年成長率分類（2025-2032 年）

• 市場概覽
• 成年人口（14歲以上）
• 兒童人口（14歲以下）

全球下一代糖尿病藥物傳輸市場按適應症和複合年成長率分類（2025-2032 年）

• 市場概覽
• 1型糖尿病
• 2型糖尿病

全球下一代糖尿病藥物傳輸市場（按最終用戶和複合年成長率分類）（2025-2032 年）

• 市場概覽
• 診斷/診所
• 加護病房（ICU）
• 家庭醫療保健

全球下一代糖尿病藥物傳輸技術市場規模及複合年成長率（2025-2032 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2024 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2022-2024年營收年比比較

主要企業簡介

• Novo Nordisk A/S（Denmark）
• Medtronic Plc（Ireland）
• Abbott Laboratories（United States）
• Dexcom, Inc.（United States）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Insulet Corporation（United States）
• Tandem Diabetes Care, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• MannKind Corporation（United States）
• Becton, Dickinson and Company（BD）（United States）
• Ypsomed AG（Switzerland）
• Senseonics Holdings, Inc.（United States）
• Diabeloop SAS（France）
• Beta Bionics, Inc.（United States）
• Embecta Corp.（United States）
• Biocon Limited（India）
• Nemaura Medical Inc.（United Kingdom）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）

結論與建議

Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 36.3 billion in 2023 and is poised to grow from USD 39.31 billion in 2024 to USD 74.4 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global market for next generation diabetes therapy and drug delivery is experiencing significant growth, primarily fueled by the rising prevalence of diabetes worldwide. There is a substantial demand for more effective, user-friendly, and minimally invasive treatment options. The focus is shifting from merely managing glucose levels to developing therapies that promote weight loss, enhance cardiovascular health, and ultimately improve patients' quality of life, leading to heightened research and development efforts and market expansion. However, the analysis reveals considerable challenges, including high costs for innovative therapies and devices, which impede reimbursement and access. Additionally, lengthy and expensive regulatory approval processes, coupled with technical hurdles in creating reliable non-invasive systems and fully automated "closed-loop" management, pose significant barriers to future growth in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Diabetes Therapy Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Diabetes Therapy Drug Delivery Market Segments Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Diabetes Therapy Drug Delivery Market

The remarkable expansion of the global next generation diabetes therapy drug delivery market is primarily driven by the continuous increase in the prevalence of Type 1 and Type 2 diabetes. This growing population of individuals requiring effective management options highlights a significant demand for innovative and convenient therapeutic solutions. As more people are diagnosed, the need for advanced drug delivery systems that cater to their diverse healthcare needs becomes critical, further fueling the market's growth. Enhanced treatment alternatives not only aim to improve patient outcomes but also strive to simplify the management of diabetes, thereby addressing an ever-expanding market opportunity.

Restraints in the Global Next Generation Diabetes Therapy Drug Delivery Market

One of the significant challenges facing the Global Next Generation Diabetes Therapy Drug Delivery market is the high cost associated with these advanced therapies and devices, which often surpasses the financial capabilities of many patients. This economic burden makes it difficult for individuals to afford necessary treatments. Additionally, obtaining reimbursement from both public and private insurers poses a substantial hurdle, further limiting patient access to these crucial therapies, particularly in emerging markets where healthcare resources may be more constrained. Addressing these financial barriers is essential to ensuring broader accessibility and adoption of innovative diabetes treatments.

Market Trends of the Global Next Generation Diabetes Therapy Drug Delivery Market

The global next generation diabetes therapy drug delivery market is increasingly driven by the demand for interoperability and connectivity among devices. Patients are seeking personalized solutions that enable them to integrate their continuous glucose monitors (CGMs) with insulin pumps, fostering a trend towards open-protocol systems. This shift is not only enhancing patient autonomy but also optimizing diabetes management by facilitating seamless data exchange. As manufacturers respond to this consumer-driven demand, we can anticipate innovative drug delivery systems that prioritize user-friendly applications, increased data accessibility, and improved therapeutic outcomes, ultimately shaping a more interconnected landscape in diabetes care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Demographic & CAGR (2025-2032)

• Market Overview
• Adult Population (>14years)
• Child Population (14years)

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes

Global Next Generation Diabetes Therapy Drug Delivery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic/Clinics
• ICUs
• Home Healthcare

Global Next Generation Diabetes Therapy Drug Delivery Market Size & CAGR (2025-2032)

• North America (Product, Demographic, Indication, End User)
  • US
  • Canada
• Europe (Product, Demographic, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Demographic, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Demographic, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Demographic, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SAS (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Embecta Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nemaura Medical Inc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations